EMPOWER-Lung 3 Trial Results Find Cemiplimab Plus Chemotherapy Effective in NSCLC: Ana Baramidze, MD

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, discussed how the EMPOWER-Lung 3 trial reaffirmed the efficacy of cemiplimab plus chemotherapy in the treatment of non-small cell lung cancer (NSCLC) compared with chemotherapy alone.

This transcript has been lightly edited for clarity; captions are auto-generated.

Transcript

What were the 5-year efficacy results of EMPOWER Lung 3, and how do they compare with previous data?

Prior efficacy results for overall survival from the phase 3 EMPOWER-Lung 3 trial found that cemiplimab plus chemotherapy remains superior to chemotherapy alone, and with a median follow-up of 60.9 months, there was a 21.1-month median overall survival for patients treated with cemiplimab plus chemotherapy vs 12.9 months for chemotherapy alone. And the results also showed 8.2 months median progression-free survival for patients treated with cemiplimab plus chemotherapy vs 5.5 months for chemotherapy alone, a 44% objective response rate for patients treated with cemiplimab combination vs 22% for chemotherapy alone, and 16.4 months median duration of response for patients treated with cemiplimab combination vs 7.3 months for chemotherapy alone. And this data from the EMPOWER-Lung 3 trial are generally consistent with previously reported data, which led to the regulatory approval of cemiplimab.